Collegium Pharmaceutical, Inc. (COLL) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Keros Therapeutics, Inc.

Ligand Pharmaceuticals, Inc.

Innoviva, Inc.

Collegium Pharmaceutical, Inc.

ImmunityBio, Inc.

Ardelyx, Inc.

Revance Therapeutics, Inc.

Day One Biopharmaceuticals, Inc.

Morphic Holding, Inc.

ACELYRIN, Inc.

EQRx, Inc.

Why is Collegium Pharmaceutical, Inc. ?

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.55

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.55
The company has been able to generate a Return on Capital Employed (avg) of 18.24% signifying low profitability per unit of total capital (equity and debt)

Healthy long term growth as Net Sales has grown by an annual rate of 18.57% and Operating profit at 64.23%

INVENTORY TURNOVER RATIO(HY) Highest at 9.28 times
DEBTORS TURNOVER RATIO(HY) Highest at 3.56 times
NET SALES(Q) Highest at USD 188 MM

With ROCE of 16.93%, it has a fair valuation with a 1.78 Enterprise value to Capital Employed

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 48.10%, its profits have fallen by -29.6%

High Institutional Holdings at 100%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Collegium Pharmaceutical, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Collegium Pharmaceutical, Inc. for you?

Medium Risk, High Return

Absolute

Risk Adjusted

Volatility

Collegium Pharmaceutical, Inc.

54.7%

0.92

40.08%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

18.57%

EBIT Growth (5y)

64.23%

EBIT to Interest (avg)

1.55

Debt to EBITDA (avg)

3.22

Net Debt to Equity (avg)

3.17

Sales to Capital Employed (avg)

0.60

Tax Ratio

32.54%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

18.24%

ROE (avg)

24.91%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.25

EV to EBIT

10.52

EV to EBITDA

4.89

EV to Capital Employed

1.78

EV to Sales

2.62

PEG Ratio

Dividend Yield

ROCE (Latest)

16.93%

ROE (Latest)

28.03%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bearish

Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

INVENTORY TURNOVER RATIO(HY)

Highest at 9.28 times

DEBTORS TURNOVER RATIO(HY)

Highest at 3.56 times

NET SALES(Q)

Highest at USD 188 MM

-14What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD 203.48 MM

PRE-TAX PROFIT(Q)

At USD 17.6 MM has Fallen at -29.39%

RAW MATERIAL COST(Y)

Grown by 7.9% (YoY

NET PROFIT(Q)

At USD 12.39 MM has Fallen at -24.59%

Here's what is working for Collegium Pharmaceutical, Inc.

Net Sales

Highest at USD 188 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Inventory Turnover Ratio

Highest at 9.28 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio

Highest at 3.56 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Depreciation

Highest at USD 56.61 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Collegium Pharmaceutical, Inc.

Pre-Tax Profit

At USD 17.6 MM has Fallen at -29.39%

over average net sales of the previous four periods of USD 24.93 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Operating Cash Flow

Lowest at USD 203.48 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Net Profit

At USD 12.39 MM has Fallen at -24.59%

over average net sales of the previous four periods of USD 16.43 MM

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Raw Material Cost

Grown by 7.9% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales